誉衡药业11月11日获融资买入1570.19万元，融资余额3.71亿元

Group 1 - The core viewpoint of the news is that Yuheng Pharmaceutical's stock performance and financial metrics indicate a mixed outlook, with a notable decrease in revenue but an increase in net profit [1][2]. - As of November 11, Yuheng Pharmaceutical's stock price remained unchanged, with a trading volume of 148 million yuan and a net financing outflow of 847,300 yuan [1]. - The company's financing balance is 371 million yuan, accounting for 4.94% of its market capitalization, which is above the 60th percentile of the past year [1]. Group 2 - For the period from January to September 2025, Yuheng Pharmaceutical reported a revenue of 1.665 billion yuan, a year-on-year decrease of 10.36%, while the net profit attributable to shareholders increased by 32.85% to 244 million yuan [2]. - The number of shareholders increased by 2.88% to 105,500, while the average number of circulating shares per person decreased by 2.80% to 19,869 shares [2]. - The company has distributed a total of 692 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3].